{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.4","upperLimit":"99.5","value":"80.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Disease control was defined as the percentage of participants with a BOR of CR, PR, or stable disease (SD) by investigator assessment per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.","id":"OG000","title":"INCB099280 400 mg BID Plus Axitinib 5 mg BID"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set. Confidence intervals were calculated using the Clopper-Pearson method. In order to have a best overall response of SD, overall response must have met the SD criteria at least once after a minimum of 5 weeks from the start of treatment.","reportingStatus":"POSTED","timeFrame":"up to 335 days","title":"Part 1: Disease Control","type":"SECONDARY","unitOfMeasure":"percentage of participants"}